📣 Announcing a Milestone in Affordable Healthcare At SmithRx, we’re proud to announce a major milestone in our mission to make healthcare more affordable and accessible. We’re introducing Stelara biosimilars to our Connect 360 Autoimmune program, a move that’s projected to save our employer clients $14.5 million annually in prescription drug costs. “Our Connect 360 program was built because we saw a better way to generate real, tangible savings for our members and clients,” explains Alan Pannier, Pharm D,MBA, our own SVP of Clinical Strategy. “Leveraging our drug pathways engine we are able to connect patients with the innovative drug alternatives on the market today, like biosimilars. Our technology coupled with unparalleled, hands-on service has allowed us to shatter the perception that prescription benefits have to be expensive and complicated." 🧡 We are incredibly proud to be the first PBM to meaningfully embrace biosimilars to drive savings for clients. It's a game-changer for the industry, and we’re honored to lead the way. Since we rolled out Connect 360 Autoimmune in 2023, we’ve already transitioned over 90% of our members to the biosimilar, Yusimry, and lowered Humira spend for clients by 90%. Building on this success, the addition of a Stelara biosimilar is a major step forward in tackling some of the most expensive drugs in the country. By embracing biosimilars, we’re redefining what’s possible in pharmacy benefits. This is about creating a system that works for everyone, where savings are real, transparency is non-negotiable, and innovation drives meaningful change. 🤝 Join us in shaping the future of healthcare. If you’re an employer, benefits advisor, or simply someone who believes in a better way to manage pharmacy benefits, let’s connect. Together, we can build a future where everyone has access to the care they deserve. https://lnkd.in/gKM2-NsF #PharmacyBenefits #Biosimilars #pbms #SmithRx
